Compare Kyndryl Holdings Inc (KD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Kyndryl Holdings Inc trades at $11.75 (market cap $2.59B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 49.2× Kyndryl Holdings Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| KD | VRTX | |
|---|---|---|
Market Cap | $2.59B | $127.55B |
Volume | 5,354,348 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $29.76 | $557.96 |
52-Week Low | $10.59 | $407.37 |
Typical Hold Time | 36 Days | 120 Days |
Enterprise Value | $5.41B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $11.75, up 2.62% with bearish technical signals but improving fundamentals. The company reported positive net income of $252M in 2025 after years of losses, with revenue stabilizing around $15B. Recent news highlights AI initiatives including a new Dallas innovation lab and healthcare IT acquisition. Analyst consensus is mixed with 71% hold ratings but a $14.67 price target suggesting 25% upside potential.
KD shows fundamental improvement with profitability returning, though earnings misses and competitive pressures remain risks. The stock trades at reasonable valuations (P/S 0.18x) but faces execution challenges in its AI transformation. Institutional interest is building with recent purchases, but technical weakness suggests near-term consolidation likely before sustained upward movement.
Vertex Pharmaceuticals (VRTX) trades at $510.08, up 0.88% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $12B revenue and $4B net income, though recent quarterly earnings show inconsistent performance against expectations. Positive Phase 2b data for inaxaplin in kidney disease highlights pipeline progress beyond cystic fibrosis dominance.
Wall Street maintains strong bullish sentiment with 84% buy ratings and $573.50 consensus target, but risks include competitive pressures and reliance on CF franchise. The stock's premium valuation (P/E 29.31) requires continued execution on pipeline expansion to justify upside potential amid technical resistance near $515.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
